{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-018419","form_type":"8-K","ticker":"VBIO","cik":"0001787740","company_name":"Valion Bio, Inc.","filed_at":"2025-02-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.868070+00:00","generated_at":"2026-05-26T22:57:57.186810+00:00","sec_items":["1.01","5.03","3.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Tivic Health acquires exclusive worldwide license for Statera's TLR5 agonist Entolimod for ARS","bullets":["License fee of $1.5M ($300K cash + $1.2M in stock and preferred) for exclusive rights to Entolimod for ARS.","Potential milestones up to $1.75M for ARS and $6.5M for additional indications, total $8.25M.","Exclusive option to expand license to five additional indications including Lymphocyte Exhaustion and Neutropenia.","Entolimod has FDA Fast Track & Orphan Drug designation; prior investment $140M; potential BLA filing within 24 months.","Statera gets Board seat nomination; Tivic to hold stockholder vote on Series A conversion within 120 days."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-018419","json":"https://secwatch.observer/filing/0000950170-25-018419.json","markdown":"https://secwatch.observer/filing/0000950170-25-018419.md","text":"https://secwatch.observer/filing/0000950170-25-018419.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787740/000095017025018419/0000950170-25-018419-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787740/000095017025018419/tivc-20250210.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T22:57:57.186810+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}